SCYX
SCYNEXIS INC
$4.45
-5.52%
$43.3M
No data for this timeframe.
Vol
Market Cap$43.3M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$1.3M
Inst. Activity1 buys / 0 sells
Insider Activity2B / 0S
Reddit Sentiment33° Cool
SEC Reports3
Press Releases2
Recent Activity
May 22, 2026
SEC
SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8M votes for and 6.7M
8-K — Impact 4/10
May 22, 2026
other
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 <pre>SCYNEXIS’
May 11, 2026
SEC
SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than the consensus estima
PRESS-RELEASE — Impact 7/10
Apr 20, 2026
SEC
Steven C. Gilman, a board member of SCYNEXIS Inc., notified the company of his intent to retire and not stand for re-ele
8-K — Impact 3/10
Apr 1, 2026
Insider
Angulo Gonzalez David bought 108,695 shares
Chief Executive Officer @ $0.00 ($0.00)
Apr 1, 2026
Insider
Angulo Gonzalez David bought 108,695 shares
Chief Executive Officer @ $0.00 ($0.00)
Jan 29, 2026
Insider
Macleod ivor sold 129,833 shares
Chief Financial Officer @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
46,095 shares ($29.1K)
Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$33.55 (Oct 2025)
Current $4.36
Low $24.00
Median $32.00
High $44.64
3 analysts
$24.00
$44.64
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 28, 2025 | Guggenheim | MAINTAIN | Buy → Buy |
| Apr 1, 2024 | Cantor Fitzgerald | REITERATE | Overweight |
| Aug 15, 2023 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Apr 3, 2023 | Guggenheim | MAINTAIN | Buy |
| Apr 3, 2023 | Ladenburg Thalmann | REITERATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.51 ▲ +38.7% | $-0.56 — $-0.40 | 55% YoY | 3 |
| Next Q | $-0.51 ▲ +36.7% | $-0.56 — $-0.40 | 63% YoY | 3 |
| Current FY | $-4.08 ▼ -21.4% | $-4.24 — $-3.92 | -200% YoY | 2 |
| Next FY | $-2.52 ▼ -26.0% | $-2.72 — $-2.32 | 38% YoY | 2 |
Latest Reports
NEUTRAL
8-K
4/10
SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8M votes for and 6.7M
May 22, 2026
BEARISH
PRESS-RELEASE
7/10
SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than the consensus estima
May 11, 2026
BULLISH
Press
7/10
Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a clinical-stage oral therapy for autosomal dominant
Mar 31, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.1M | — |
| RENAISSANCE TECHNOLOGIES LLC | $111.3K | — |
| MORGAN STANLEY | $29.1K | DOUBLED |
| BANK OF AMERICA CORP | $1.2K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Angulo Gonzalez | BUY | $0.00 |
| Apr 1, 2026 | Angulo Gonzalez | BUY | $0.00 |
| Jan 29, 2026 | Macleod ivor | A | $0.00 |
| Jan 29, 2026 | Angulo Gonzalez | A | $0.00 |
| Jan 29, 2026 | Sukenick Scott | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
4 institutional holders with $1.3M total value (1,986,308 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,762,322 | $1.1M | 88.7% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 176,000 | $111.3K | 8.9% | — |
| 3 | MORGAN STANLEY | 46,095 | $29.1K | 2.3% | DOUBLED +193.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 1,891 | $1.2K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 15,700 | 46,095 | +193.6% | $29.1K | 2025-Q4 |
| CITADEL ADVISORS LLC | TRIM | 106,932 | 74,357 | -30.5% | $70.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 12,900 | 106,932 | +728.9% | $129.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 15,008 | 84,567 | +463.5% | $102.3K | 2024-Q4 |
3 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Angulo Gonzalez David | Chief Executive Officer | BUY | 108,695 | $0.00 | $0.00 |
| Apr 1, 2026 | Angulo Gonzalez David | Chief Executive Officer | BUY | 108,695 | $0.00 | $0.00 |
| Jan 29, 2026 | Macleod ivor | Chief Financial Officer | A | 129,833 | $0.00 | $0.00 |
| Jan 29, 2026 | Angulo Gonzalez David | Chief Executive Officer | A | 391,333 | $0.00 | $0.00 |
| Jan 29, 2026 | Sukenick Scott | Chief Legal Officer | A | 129,833 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8
May 22, 2026
BEARISH
PRESS-RELEASE
7/10
SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than
May 11, 2026
NEUTRAL
8-K
3/10
Steven C. Gilman, a board member of SCYNEXIS Inc., notified the company of his intent to retire and
Apr 20, 2026
Historical analyst distribution (last covering-analyst action Oct 2025): 89% buy across 9 analysts — 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$33.55 mean target (Oct 2025)
$24.00 Low
$44.64 High
| Metric | Value |
|---|---|
| Current Price | $4.36 |
| Target Low | $24.00 |
| Target Mean | $33.55 |
| Target Median | $32.00 |
| Target High | $44.64 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.51 | $-0.56 | $-0.40 | 54.8% | +38.7% | 1↑ 0↓ | $0.0B | -94.1% | 3 |
| Next Q 2026-09-30 |
$-0.51 | $-0.56 | $-0.40 | 62.7% | +36.7% | 0↑ 1↓ | $0.0B | -74.0% | 3 |
| Current FY 2026-12-31 |
$-4.08 | $-4.24 | $-3.92 | -200.0% | -21.4% | 2↑ 1↓ | $0.0B | -94.4% | 2 |
| Next FY 2027-12-31 |
$-2.52 | $-2.72 | $-2.32 | 38.2% | -26.0% | 0↑ 1↓ | $0.0B | 478.6% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.507 | |
| 7d ago | $-0.693 | +0.187 |
| 30d ago | $-0.827 | +0.320 |
| 60d ago | $-1.040 | +0.533 |
| 90d ago | $-1.200 | +0.693 |
12 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 15 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 28, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 1, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Aug 15, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Apr 3, 2023 | Guggenheim | MAINTAIN | — | Buy |
| Apr 3, 2023 | Ladenburg Thalmann | REITERATE | — | Buy |
| Mar 1, 2023 | Guggenheim | INITIATE | — | Buy |
| May 13, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 31, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Jun 7, 2021 | Aegis Capital | MAINTAIN | — | Buy |
| Apr 12, 2021 | Aegis Capital | MAINTAIN | — | Buy |
| Jan 22, 2021 | Guggenheim | INITIATE | — | Buy |
| Jan 6, 2021 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Dec 28, 2020 | HC Wainwright & Co. | REITERATE | — | Buy |
| Apr 23, 2020 | Aegis Capital | MAINTAIN | — | Buy |
| Oct 16, 2018 | Maxim Group | MAINTAIN | Buy | Buy |
| Jun 27, 2018 | Maxim Group | INITIATE | — | Buy |
| May 24, 2018 | Ladenburg Thalmann | INITIATE | — | Buy |
| Apr 10, 2018 | Seaport Global | INITIATE | — | Buy |
| Oct 24, 2017 | Guggenheim | INITIATE | — | Buy |
| Jan 31, 2017 | Aegis Capital | INITIATE | — | Buy |
| Oct 20, 2016 | HC Wainwright & Co. | INITIATE | — | Buy |
| Oct 7, 2016 | WBB Securities | UPGRADE | Buy | Strong Buy |
| Aug 17, 2016 | Guggenheim | INITIATE | — | Buy |
| Aug 9, 2016 | WBB Securities | UPGRADE | Speculative Buy | Buy |
| Mar 28, 2016 | Brean Capital | INITIATE | — | Buy |
| Dec 29, 2015 | WBB Securities | INITIATE | — | Speculative Buy |
| Jun 10, 2015 | Needham | INITIATE | — | Buy |
| Jun 2, 2014 | JMP Securities | INITIATE | — | Market Perform |
| May 29, 2014 | Canaccord Genuity | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 18, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 17, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$SCYX: Micro-cap biotech with multi-bagger potential
▲ 1
💬 0
⚡ 0.5
May 22, 2026
other
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 <pre>SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adju
May 13, 2026
earnings_calendar
SCYX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="justify">JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data=5
May 7, 2026
other
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
<p>JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused
May 7, 2026
earnings_calendar
SCYX Q1 2026 Earnings Scheduled — 2026-05-07
Mar 31, 2026
offering
SCYNEXIS Announces $40.0 Million Private Placement
<p align="justify">JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data
Mar 31, 2026
m_and_a
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
<p>SCYNEXIS will host a conference call on <strong>March 31, 2026 at 8:30 a.m. ET </strong>to provide a corporate update.</p>
Mar 4, 2026
earnings
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
<p align="justify">JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data